Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Last trade$3.28
Day change-$0.175 (-5.07%)
Day range$3.14 – $3.58
Volume224,008
Market cap$530M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$529.93M
Price / earnings
—
Price / book
46.6×
Price / sales
—
EV / sales
—
EV / EBITDA
-35.36×
Profitability
Earnings per share
-$0.10
Return on assets
-128.66%
Return on equity
-135.62%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
19.48×
Quick ratio
19.48×
Cash ratio
12.27×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$14.7M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for INDP, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.45M
$1.67M
$5.31M
$1.13M
$2.29M
$1.76M
$1.69M
$1.68M
Research and development
$363.13K
$491.13K
$2.85M
$1.52M
$2.17M
$2.81M
$2.48M
$1.47M
Total operating expenses
$1.81M
$2.16M
$8.16M
$2.65M
$4.46M
$4.57M
$4.17M
$3.14M
Operating income
-$1.81M
-$2.16M
-$8.16M
-$2.65M
-$4.46M
-$4.57M
-$4.17M
-$3.14M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$1.79M
-$2.54M
-$8.11M
-$2.98M
-$5.23M
-$4.53M
-$4.13M
-$3.07M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.79M
-$2.54M
-$8.11M
-$2.98M
-$5.23M
-$4.53M
-$4.13M
-$3.07M
Net income attributable to common shareholders
-$1.79M
-$2.54M
-$8.11M
-$2.98M
-$5.23M
-$4.53M
-$4.13M
-$3.07M
EBITDA
-$1.81M
-$2.16M
-$8.16M
-$2.65M
-$4.46M
-$4.57M
-$4.17M
-$3.14M
Basic earnings per share
-$0.02
-$0.23
-$4.52
-$2.98
-$9.09
-$9.11
-$10.59
-$9.04
Diluted earnings per share
-$0.02
-$0.23
-$4.52
-$2.98
-$9.09
-$9.11
-$10.59
-$9.04
Recent news
Company coverage with links to the original publishers.
Abbott Cooper PLLC is investigating potential fiduciary duty violations by the board of Indaptus Therapeutics in connection with a private placement of preferred stock. The investigation targets stockholders who held shares prior to December 22, 2025.
Indaptus Therapeutics, a clinical-stage biotechnology company, highlights its accomplishments in 2024 and outlines its strategic goals for 2025, including the launch of a combination trial with BeiGene's tislelizumab and the expansion of its Decoy20 clinical trial.
Indaptus Therapeutics presented positive interim safety data from a Phase 1 trial of its lead compound Decoy20, which showed an acceptable safety profile and signs of anti-tumor activity. The company plans to combine Decoy20 with a PD-1 inhibitor in a new cohort.
Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20